In a recent development in the realm of intellectual property litigation, Freshfields has successfully represented Moderna in a patent dispute against BioNTech and Pfizer at the Düsseldorf regional court. The court’s decision mandates that BioNTech and Pfizer compensate Moderna for patent infringement related to the mRNA vaccine technology. The exact amount of damages is yet to be determined.
BioNTech, backed by legal representation from Taylor Wessing, plans to appeal the decision. They maintain their position that the contested patent is invalid. The appeal is pending before the European Patent Office’s Technical Board of Appeal.
This decision is bound to add another layer of complexity to the already ongoing COVID-19 vaccine-related antitrust case between these pharmaceutical giants. For more detailed coverage, access the original article here.